Treatment with teclistamab, administered subcutaneously at a dose of 1500 µg/kg once weekly, led to a high response rate and an encouraging safety profile in patients with relapsed/refractory multiple myeloma.
Recent Content
- FDA gives green light to first human trial testing cancer drug GTB-5550
- Tumour-intrinsic features shape T cell differentiation through precursor to symptomatic multiple myeloma
- (no title)
- (no title)
- Scientists test treatment strategy using ‘glioblastoma on a chip’
- (no title)
- (no title)
- (no title)
- Prostate cancer tool may cut risk for women in radiation therapy
- Predicting adverse events for risk stratification of chemotherapy based stem cell mobilization in multiple myeloma